| __timestamp | BeiGene, Ltd. | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 6930000 | 675200000 |
| Thursday, January 1, 2015 | 7311000 | 771800000 |
| Friday, January 1, 2016 | 20097000 | 1205500000 |
| Sunday, January 1, 2017 | 62602000 | 1146500000 |
| Monday, January 1, 2018 | 195385000 | 1125800000 |
| Tuesday, January 1, 2019 | 388249000 | 1166100000 |
| Wednesday, January 1, 2020 | 600176000 | 1175500000 |
| Friday, January 1, 2021 | 990123000 | 1111400000 |
| Saturday, January 1, 2022 | 1277852000 | 1210100000 |
| Sunday, January 1, 2023 | 1504501000 | 1274600000 |
Unleashing insights
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of BeiGene, Ltd. and Perrigo Company plc from 2014 to 2023. Over this period, BeiGene's SG&A expenses skyrocketed by over 21,500%, reflecting its aggressive expansion and investment in global markets. In contrast, Perrigo's expenses grew by a modest 89%, indicating a more stable and controlled financial strategy.
By 2023, BeiGene's SG&A expenses reached approximately 1.5 billion, surpassing Perrigo's 1.27 billion. This shift highlights BeiGene's rapid growth trajectory and its commitment to scaling operations. Investors and industry analysts should note these trends as they provide insights into each company's strategic priorities and market positioning.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Perrigo Company plc
Operational Costs Compared: SG&A Analysis of Novartis AG and Perrigo Company plc
Operational Costs Compared: SG&A Analysis of GSK plc and BeiGene, Ltd.
Cost Management Insights: SG&A Expenses for Biogen Inc. and BeiGene, Ltd.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Insmed Incorporated
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Catalent, Inc.
Comparing SG&A Expenses: BeiGene, Ltd. vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: BeiGene, Ltd. vs MannKind Corporation
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Geron Corporation
Selling, General, and Administrative Costs: Cytokinetics, Incorporated vs Perrigo Company plc